Evonik broke ground on an €80 million biotech expansion at its Slovak Fermas site to boost pharmaceutical intermediate production via fermentation, scheduled for completion in early 2028.
Evonik announced plans to construct a new GMP-compliant LNP drug production facility in Vancouver with over 150 million CAD investment, targeting 2029 completion. The project will triple existing capa
Evonik reported a 24% year-on-year increase in adjusted EBITDA to €630 million for Q2 2026, raising its full-year outlook to €2–2.2 billion. Growth stemmed from an 11% sales increase and opportunities
Evonik raised its 2026 full-year adjusted EBITDA guidance to €2–2.2 billion following a Q2 forecast of €600–650 million, up 23% year-over-year. The upgrade stems from higher volumes and prices, though
Evonik plans to cut 3,200 jobs globally by 2029 and discontinue its unprofitable polyester business due to weak market dynamics and European structural disadvantages. The move aims to enhance efficien
Swiss logistics group Kuehne+Nagel raised its 2026 operating profit guidance to 1.25-1.40 billion Swiss francs, citing cost discipline despite short-term sea logistics losses due to Middle East disrup
Evonik Industries inaugurated an expansion of its specialty amine facility in Nanjing, investing double-digit millions to boost supply for polyurethane and epoxy applications. The upgraded plant utili
Evonik unveils advanced polymer solutions at CHINAPLAS 2026 for sectors including new energy vehicles, hydrogen, and personalized medicine. The company also confirmed successful trial production of it
Evonik outlined a balanced global growth strategy at the India Chemical Industry Outlook Conference, emphasizing agility and partnerships. The company cited geopolitical uncertainty as a key driver fo
Evonik maintains its earnings outlook and expects no demand recovery until 2026. Q4 operating profits declined yet beat estimates, supported by anticipated savings from its reorganization program.
Evonik plans to expand HTPB production capacity in Germany, with additional capacity scheduled for Q2 2027. The company also announced plans for a new production facility in Asia.
Evonik has expanded its Hiformer PFAS-free liquid additive series to Asia, introducing two new formulations for polyolefin films that improve processing stability and reduce energy consumption.
Evonik announced higher net profit in preliminary results, with adjusted EBITDA projected in line with guidance. The company also plans to cut 2,000 jobs as part of its ongoing reorganization program.
Evonik executive urges Argentina to industrialize Vaca Muerta shale resources beyond commodity exports to revive chemical manufacturing amid economic instability and plant closures.
Evonik exceeded analyst estimates despite reporting a Q3 net loss driven by restructuring costs and lower volumes. The company confirmed its earnings outlook following the financial decline.
ChemBrief